Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 16/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL983406 | 0.84 | EPHX2 (0.38) | NR3C1EPHX2MEN1KMT2A | |
| SCHEMBL985083 | 0.83 | NR3C1 (0.44) | NR3C1EPHX2 | |
| SCHEMBL4969666 | 0.83 | EPHX2 (0.41) | EPHX2POLBMEN1KMT2A | |
| SCHEMBL984371 | 0.77 | RHOA (0.42) | NR3C1 | |
| SCHEMBL5644235 | 0.76 | NR3C1 (0.69) | NR3C1 | |
| SCHEMBL983364 | 0.76 | NR3C1 (0.44) | NR3C1POLB | |
| SCHEMBL984006 | 0.76 | NR3C1 (0.39) | NR3C1EPHX2 | |
| SCHEMBL15047780 | 0.76 | NR3C1 (0.39) | NR3C1EPHX2MEN1KMT2A | |
| SCHEMBL7167931 | 0.75 | NR3C1 (0.67) | NR3C1 | |
| SCHEMBL5644049 | 0.74 | NR3C1 (0.68) | NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960351-B1 | PROPIONAMIDE COMPOUNDS AS ANTIINFLAMMATORY AGENTS | HOFFMANN LA ROCHE (CH) | 2013-06-19 | — | — | EP | claimed |
| US-7868031-B2 | Propionamide compounds as antiinflammatory agents | ROCHE PALO ALTO LLC (US) | 2011-01-11 | — | — | US | claimed |
| US-20070135500-A1 | Propionamide compounds as antiinflammatory agents | ROCHE PALO ALTO LLC | 2007-06-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135500-A1 | Propionamide compounds as antiinflammatory agents | PTGS1, PTGER1, PTGES3 | NR3C1 707/4885EPHX2 625/4885POLB 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.